Lobectomy versus stereotactic body radiotherapy for stage I non–small cell lung cancer: Post hoc analysis dressed up as level-1 evidence? Bryan F. Meyers,

Slides:

Advertisements

Similar presentations

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Advertisements

Lost in translation The Journal of Thoracic and Cardiovascular Surgery

Stephen R. Broderick, MD, MPHS

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer? Traves D. Crabtree, MD, Varun Puri,

Lung cancer screening: No more excuses

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Ground glass opacity of the lung: The veil that needs lifting

National Patterns of Care and Outcomes After Combined Modality Therapy for Stage IIIA Non–Small-Cell Lung Cancer Aalok P. Patel, BS, Traves D. Crabtree,

John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N

Victor van Berkel, MD, PhD

Varun Puri, MD, Andrew Tran, MS, Jennifer M. Bell, BS, Traves D

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial Stacey.

Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer Usman Ahmad, MD, Traves D. Crabtree,

Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer Pamela Samson, MD, MPHS, Traves.

Shawn S. Groth, MD, Bryan M. Burt, MD

Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival Pamela Samson, MD, MPHS, Traves.

The National Surgical Quality Improvement Program risk calculator does not adequately stratify risk for patients with clinical stage I non–small cell.

The lord of the rings Antonio Miceli, MD, PhD

Is tissue the issue? Brian E. Louie, MD, MHA, MPH, FRCSC, FACS

Yang Zhang, MD, Haiquan Chen, MD, PhD

Treatment Outcomes in Stage I Lung Cancer

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Support Your Specialty

The search for the holy grail of lobectomy

It's not “just a shunt” but sometimes it should be…

Management of stage IIIA (N2) non–small cell lung cancer: A transatlantic perspective Gaetano Rocco, MD, Katie Nason, MD, MPH, Alex Brunelli, MD, Gonzalo.

Military surgeons just want to have fun

Do we need a bibliometrician to know which way the wind is blowing?

A first start for lung transplantation?

Stephen R. Broderick, MD, MPHS

Extent of Lymphadenectomy Is Associated With Improved Overall Survival After Esophagectomy With or Without Induction Therapy Pamela Samson, MD, MPHS,

Get it right the first time

Commentary: It's time to check our bias: Ensuring health equity for patients with lung cancer Pamela Samson, MD, MPHS The Journal of Thoracic and Cardiovascular.

Michael Lanuti, MD The Journal of Thoracic and Cardiovascular Surgery

Yusuke Takahashi, MD, PhD, Prasad S. Adusumilli, MD

Resection of primary lung cancer with incidental pleural seeding: Seeds of change or reap what you sow? Jules Lin, MD The Journal of Thoracic and Cardiovascular.

Replicating the success of mitral valve repair in the aortic valve

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Commentary: Do the right thing! Ethical versus legal

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Prognosis and “granularity”: Building on staging foundations?

Adhering to Quality Measures in Esophagectomy Is Associated With Improved Survival in All Stages of Esophageal Cancer Pamela Samson, MD, MPHS, Varun.

Stephen R. Broderick, MD, MPHS, Aalok P. Patel, BS, BA, Traves D

Patterns of care in hilar node-positive (N1) non–small cell lung cancer: A missed treatment opportunity? Matthew J. Bott, MD, Aalok P. Patel, BS, Vivek.

Bryan M. Burt, MD The Journal of Thoracic and Cardiovascular Surgery

Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer Pamela Samson, MD, Aalok Patel,

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

Surveillance and the second primary lung cancer: Enhancing our understanding beyond Martini and Melamed Melanie P. Subramanian, MD, Varun Puri, MD, MSCI

The future of cardiac surgery training: A survival guide

Linda W. Martin, MD, MPH, FCCP, FACS, Gail E

Robert J. Cerfolio, MD, FACS, FCCP, Ayesha S. Bryant, MSPH, MD

The continuing challenge of congenital heart disease in China

Ralph E. Delius, MD The Journal of Thoracic and Cardiovascular Surgery

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

“The more things change…”: The challenges ahead

Aritoshi Hattori, MD, Kenji Suzuki, MD

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

Of mice and men… The Journal of Thoracic and Cardiovascular Surgery

Who should decide margin length in pulmonary excision of lung cancer?

Is there a benefit to continuing with resection of all sites of disease when clinically occult pleural metastases from non–small cell carcinoma are found?

Did you like Terminator 3 better than Terminator 2

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

Journal changes and initiatives

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Presentation transcript:

Lobectomy versus stereotactic body radiotherapy for stage I non–small cell lung cancer: Post hoc analysis dressed up as level-1 evidence? Bryan F. Meyers, MD, MPH, Varun Puri, MD, MBBS, MSCI, Stephen R. Broderick, MD, MPHS, Pamela Samson, MD, Kathleen Keogan, BS, Traves D. Crabtree, MD The Journal of Thoracic and Cardiovascular Surgery Volume 150, Issue 3, Pages 468-471 (September 2015) DOI: 10.1016/j.jtcvs.2015.06.086 Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

STARS accrued 3. 5% of expected, and ROSEL accrued 2. 3% STARS accrued 3.5% of expected, and ROSEL accrued 2.3%. A pooled analysis remains underpowered. The Journal of Thoracic and Cardiovascular Surgery 2015 150, 468-471DOI: (10.1016/j.jtcvs.2015.06.086) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions